Substandard and counterfeit antimalarial discovered in Ghana by Cooperative Program of USP, Ghana Food and Drugs Board
Substandard and counterfeit versions of thirteen key antimalarial medicines were uncovered in multiple locations across Ghana by the Medicines Quality Monitoring surveillance program, it was announced yesterday. Just a few days earlier, Ghana’s Vice President John Dramani Mahama called on member countries of the International Society of Pharmacovigilance (ISoP) who were meeting in the country’s capital, Accra, to institute effective measures that would help detect fake and counterfeit drugs.
Set up by the Ghana Food and Drugs Board (FDB) in collaboration with the US Pharmacopeial Convention (USP) and the US Agency for International Development (USAID), the program samples antimalarials across the public and private sectors. It was established in 2008 and is implemented by USP's Promoting the Quality of Medicines (PQM) initiative.
Some drugs had no active ingredients
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze